Bio-Techne Corp
SWB:TE1

Watchlist Manager
Bio-Techne Corp Logo
Bio-Techne Corp
SWB:TE1
Watchlist
Price: 53.5 EUR -1.83% Market Closed
Market Cap: €13B

Net Margin

6.3%
Current
Declining
by 10%
vs 3-y average of 16.3%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
6.3%
=
Net Income
$76.8m
/
Revenue
$1.2B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
6.3%
=
Net Income
€76.8m
/
Revenue
$1.2B

Peer Comparison

Country Company Market Cap Net
Margin
US
Bio-Techne Corp
NASDAQ:TECH
9.9B USD
Loading...
US
PerkinElmer Inc
LSE:0KHE
1.2T USD
Loading...
US
Thermo Fisher Scientific Inc
NYSE:TMO
218.1B USD
Loading...
US
Danaher Corp
NYSE:DHR
154.8B USD
Loading...
KR
Samsung Biologics Co Ltd
KRX:207940
46.3T KRW
Loading...
CH
Lonza Group AG
SIX:LONN
36B CHF
Loading...
CN
WuXi AppTec Co Ltd
SSE:603259
274.1B CNY
Loading...
US
IQVIA Holdings Inc
NYSE:IQV
39.3B USD
Loading...
US
Agilent Technologies Inc
NYSE:A
37.8B USD
Loading...
US
Mettler-Toledo International Inc
NYSE:MTD
28.2B USD
Loading...
US
Illumina Inc
NASDAQ:ILMN
22.2B USD
Loading...

Market Distribution

In line with most companies in the United States of America
Percentile
58th
Based on 15 072 companies
58th percentile
6.3%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Bio-Techne Corp
Glance View

Bio-Techne Corp. began its journey with a clear focus: to bridge the gap between biological research and practical applications, a mission that it continues to pursue with zeal. At its core, Bio-Techne operates as a pioneer in the production and distribution of biotechnology products, catering to the needs of the scientific community across the globe. The company specializes in providing essential tools for life sciences research, including proteins, antibodies, and reagents, empowering researchers to explore and innovate in fields ranging from cancer biology to neuroscience. These offerings are developed with meticulous care and a deep understanding of the scientific process, which positions Bio-Techne as a trusted ally to laboratories and research institutions worldwide. The financial heartbeat of Bio-Techne lies in its diverse portfolio, which extends into clinical diagnostics and genomics, segments that are critical in an era of personalized medicine and rapid technological advancement in healthcare. The company's revenue streams are robust, driven by a strategic blend of direct sales and collaborations with major pharmaceutical and biotech companies. Furthermore, Bio-Techne smartly leverages its acquisitions to fortify its market position, enhancing its capabilities and expanding its product lines. This agility and foresight not only enable Bio-Techne to sustain its growth trajectory but also to continually meet the ever-evolving demands of a fast-paced, innovation-driven industry.

TE1 Intrinsic Value
47.26 EUR
Overvaluation 12%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
6.3%
=
Net Income
$76.8m
/
Revenue
$1.2B
What is Bio-Techne Corp's current Net Margin?

The current Net Margin for Bio-Techne Corp is 6.3%, which is below its 3-year median of 16.3%.

How has Net Margin changed over time?

Over the last 3 years, Bio-Techne Corp’s Net Margin has decreased from 26.1% to 6.3%. During this period, it reached a low of 6% on Jun 30, 2025 and a high of 26.1% on Sep 30, 2022.

Back to Top